Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 1.42
- Piotroski Score 6.00
- Grade Buy
- Symbol (RPRX)
- Company Royalty Pharma plc
- Price $26.41
- Changes Percentage (0.04%)
- Change $0.01
- Day Low $26.33
- Day High $26.63
- Year High $31.66
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
- Last Earnings 10/11/2024
- Ex-Dividend for 5/16 Dividend 11/15/2024
- Dividend Payable 12/10/2024
- Today N/A
- Next Earnings (Estimated) 02/13/2025
- Fiscal Year End N/A
- Average Stock Price Target $51.00
- High Stock Price Target $51.00
- Low Stock Price Target $28.00
- Potential Upside/Downside N/A
- Consensus Rating Buy
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $1.78
- Trailing P/E Ratio 15.43
- Forward P/E Ratio 15.43
- P/E Growth 15.43
- Net Income $1.13 B
Income Statement
Quarterly
Annual
Latest News of RPRX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Why Is Royalty Pharma plc (RPRX) the Best Defensive Stock to Buy Now?
The article discusses the top defensive stocks to invest in, highlighting Royalty Pharma plc (NASDAQ:RPRX) as a leading choice. Royalty Pharma specializes in biopharmaceutical royalties and has a stro...
By Yahoo! Finance | 3 months ago -
Royalty Pharma PLC (RPRX): A Strategic SWOT Insight
Royalty Pharma PLC (NASDAQ:RPRX) faces threats from intense competition and regulatory changes, impacting future earnings. Despite this, the company's financial health is strong, with a diversified ro...
By Yahoo! Finance | 3 months ago -
Should You Consider Adding Royalty Pharma plc (RPRX) to Your Portfolio?
Patient Capital Management's Q2 2024 investor letter discusses the underperformance of its strategy compared to the S&P 500, attributing it to allocation and interaction effects. It mentions Royalty P...
By Yahoo! Finance | 3 months ago
